Blood-based Shield Multi-Cancer Detection (MCD) test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy Results informed National Cancer Institute ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results